Chiara Recchi obtained her PhD in Microbiology at the Pasteur Institute for her work on the virulence factors of Mycobacterium tuberculosis. Later, she extended her interest to cell biology in the laboratory of Philippe Chavrier at the Curie Institute in Paris. Here she became involved in the study of intracellular trafficking and how this controls the metastatic properties of cancer cells. She continued working in this field when in 2007 she moved to London, where she became research associate at the Imperial College in Miguel Seabra’s group. Here she developed her own project combining her expertise in intracellular trafficking with the lab’s experience in Rab proteins. This lead to one of the first descriptions of Rab27a as key to tumour progression. She then lead the Tumour Suppressor Group at the Ovarian Cancer Action Research Centre, directed by Hani Gabra, at Imperial College London. Her main focus is to understand how the tumour suppressor protein OPCML controls trafficking and signalling of Receptor Tyrosine Kinases in ovarian cancer.
et al., 2020, Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers, Cancer Gene Therapy, Vol:28, ISSN:0929-1903, Pages:18-26
et al., 2019, Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions, Nature Communications, Vol:10, ISSN:2041-1723
et al., 2019, Anti-tumorigenic and platinum-sensitizing effects of apolipoprotein A1 and apolipoprotein A1 mimetic peptides in ovarian cancer, Frontiers in Pharmacology, Vol:9, ISSN:1663-9812
et al., 2018, The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer, Embo Reports, Vol:19, ISSN:1469-221X
et al., 2017, Direct targeting of the ras GTPase superfamily through structure-based design, Current Topics in Medicinal Chemistry, Vol:17, ISSN:1568-0266, Pages:16-29